NASDAQ:CHRS - Nasdaq - US19249H1032 - Common Stock - Currency: USD
0.7617
-0.03 (-3.63%)
The current stock price of CHRS is 0.7617 USD. In the past month the price decreased by -0.82%. In the past year, price decreased by -54.93%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.61 | 337.52B | ||
AMGN | AMGEN INC | 14.22 | 158.74B | ||
GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.9 | 29.17B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
NTRA | NATERA INC | N/A | 22.58B | ||
BIIB | BIOGEN INC | 8.26 | 19.14B | ||
INSM | INSMED INC | N/A | 17.98B |
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 228 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. Its commercial product, LOQTORZI (toripalimab-tpzi), is a programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in three ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a cytolytic anti-CCR8 antibody which is in Phase I study in patients with advanced solid tumors. CHS-1000 is a humanized Fc-modified IgG1 monoclonal antibody targeting ILT4.
COHERUS ONCOLOGY INC
C/O Dennis M. Lanfear, 201 Redwood Shores Parkway, Suite 200
Redwood City CALIFORNIA 94065 US
CEO: Dennis M. Lanfear
Employees: 228
Phone: 16506493530
The current stock price of CHRS is 0.7617 USD. The price decreased by -3.63% in the last trading session.
The exchange symbol of COHERUS ONCOLOGY INC is CHRS and it is listed on the Nasdaq exchange.
CHRS stock is listed on the Nasdaq exchange.
13 analysts have analysed CHRS and the average price target is 4.78 USD. This implies a price increase of 527.15% is expected in the next year compared to the current price of 0.7617. Check the COHERUS ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
COHERUS ONCOLOGY INC (CHRS) has a market capitalization of 88.30M USD. This makes CHRS a Micro Cap stock.
COHERUS ONCOLOGY INC (CHRS) currently has 228 employees.
COHERUS ONCOLOGY INC (CHRS) has a support level at 0.76 and a resistance level at 0.76. Check the full technical report for a detailed analysis of CHRS support and resistance levels.
The Revenue of COHERUS ONCOLOGY INC (CHRS) is expected to decline by -80.67% in the next year. Check the estimates tab for more information on the CHRS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CHRS does not pay a dividend.
COHERUS ONCOLOGY INC (CHRS) will report earnings on 2025-08-06, after the market close.
COHERUS ONCOLOGY INC (CHRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).
The outstanding short interest for COHERUS ONCOLOGY INC (CHRS) is 31.44% of its float. Check the ownership tab for more information on the CHRS short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CHRS. CHRS has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months CHRS reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 50.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -35.29% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 78% to CHRS. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -38.38% and a revenue growth -80.67% for CHRS